NCGC00378430 is an inhibitor of the SIX1/EYA2 complex that significantly suppresses breast cancer-associated metastasis in vivo without significantly altering primary tumor growth.
NCGC00378430 is an inhibitor of the SIX1/EYA2 complex that significantly suppresses breast cancer-associated metastasis in vivo without significantly altering primary tumor growth.
NCGC00378430 reduces the SIX1/EYA2 interaction. NCGC00378430 partially reverses transcriptional and metabolic profiles mediated by SIX1 overexpression and reverses SIX1-induced TGF-β signaling and EMT.[1]
NCGC00378430 is well tolerated when delivered to mice and significantly suppresses breast cancer-associated metastasis in vivo without significantly altering primary tumor growth.[1]
[1] Hengbo Zhou, et al. Cancer Res. 2020 Jun 15;80(12):2689-2702.
动态评分
0.0